Mucopolysaccharidosis Type I clinical trials at UCSF
6 in progress, 3 open to eligible people
Mucopolysaccharidosis type I is a genetic disease that affects many parts of the body. UCSF is conducting a study on enzyme therapy for unborn babies with this disease. We are also keeping a record of patients with MPS I to observe their progress. Another study is collecting information on lysosomal storage diseases worldwide.
In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases
open to eligible females ages 18-50
The investigators aims to determine the the maternal and fetal safety and feasibility of in utero fetal enzyme replacement therapy in fetuses with Lysosomal Storage Diseases.
San Francisco, California
Mucopolysaccharidosis I (MPS I) Registry
open to all eligible people
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are: - To evaluate the long-term effectiveness and safety of Aldurazyme® (laronidase) - To characterize and describe the MPS I population as a whole, including the variability, progression, and natural history of MPS I - To help the MPS I medical community with the development of recommendations for monitoring patients and reports on patient outcomes to optimize patient care
Oakland, California and other locations
Registry of Patients Diagnosed With Lysosomal Storage Diseases
open to eligible people ages up to 64 years
This is an international prospective and retrospective registry of patients with Lysosomal Storage Diseases (LSDs) to understand the natural history of the disease and the outcomes of fetal therapies, with the overall goal of improving the prenatal management of patients with LSDs.
San Francisco, California
OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT
Sorry, not currently recruiting here
A multi-center randomized clinical trial to compare OTL-203 (gene therapy) with stem cell transplant (standard of care) in patients with MPS-IH (Hurler syndrome).
San Francisco, California and other locations
JR-171-101 Study in Patients With MPS I
Sorry, in progress, not accepting new patients
Phase I/II, open label, multicenter, multinational (Japan, Brazil and the US) extension study of JR-171-101 for the treatment of MPS I
Oakland, California and other locations
(LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
Sorry, in progress, not accepting new patients
Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 10 years following exposure to SB-318, SB-913, or SB-FIX.
Oakland, California and other locations
Our lead scientists for Mucopolysaccharidosis Type I research studies include Paul Harmatz Tippi Mackenzie.
Last updated: